Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1473-1483

  Szucs, Thomas D ^a   Largeron, Nathalie ^b   Dedes, Konstantin J ^c   Rafia, Rachid ^d   Bénard, Stève ^d,e  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b SANOFI PASTEUR   (France)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Stève Consultants   (France)

^e NONE   (France)

Author keywords

Cervical cancer screening; Cost effectiveness; Human Papillomavirus; Switzerland; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CHILD; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; FEMALE; HEALTH CARE COST; HISTORY; HUMAN; MAJOR CLINICAL STUDY; PARAMETER; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SWITZERLAND; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; COST-BENEFIT ANALYSIS; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; MARKOV CHAINS; MASS IMMUNIZATION; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SWITZERLAND; UTERINE CERVICAL NEOPLASMS;

EID: 44349147211     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X297826     Document Type: Article

References (58)

1. EKIF. Directive and recommendation no. 21: HPV vaccination recommendation. July 2007
2. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907
3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8
4. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-22
5. Persson G, Dahlof LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 1993;20:10-3
6. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571-8
7. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73
8. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5
9. Von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-603
10. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64
11. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91:935-41
12. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 2007;356:1928-43
13. The FUTURE II Study Group. Quadrivalent vaccine against Human Papillomavirus to prevent high-grade cervical lesions. New Engl J Med 2007;356:1915-27
14. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71
15. Kulasingam SL, Myers ER. Potential heakh and economic impact of adding a human papillomavirus vaccine to screening programs. J Am Med Assoc 2003;290:781-9
16. Kulasingam SL, Bénard S, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. R Cost Eff Resour Alloc [in press]
17. www.ofs.ch [last accessed 28 November 2007]
18. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888-95
19. Pierre Pury. Cancer in Switzerland - statistics of incidence 1985-2003. Association of Swiss Cancer Registries - June 2006 (vol 1 and 2)
20. Martin X. L'hystérectomie élargie laparoscopico-vaginale dans le traitement des cancers du col utérin 1997, Thèse
21. Lamblin G. Association radio-chirurgicale dans le traitement du cancer du col utérin de plus de 4 cm 2001, Thèse
22. Siebert U, Muth C, Sroczynski G, et al. Dünnschichtprä parationen und computergestützte Untersuchungen von Zervixabstrichen im Rahmen der Krebsfrüherkennung - Medizinische Effektivität, gesundheitsökonomische Evaluation und systematische Entscheidungsanalyse [Liquid-based preparation and computer-assisted examination of cervical smears. Clinical effectiveness, economic evaluation, and systematic decision analysis]. Health Technology Assessment, vol 35 (Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security). St. Augustin: Asgard; 2003. [444 pages]
23. http://www.who.int [last accessed 28 November 2007]
24. Monsonego J, Breugelmans G, Bouée S, et al. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynecol Obstet Fertil 2007;35:107-13
25. Gieseking F, Petry KU, Hillemanns P, et al. Incidence, prevalence and costs of treating genital warts in the pre-HPV vaccine era in Germany. Florence: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); November 2005
26. Balthasar H, Spencer B, Addor V. Indicateurs de santé sexuelle et reproductive en Suisse - Monitorage. Swiss Health Observatory 2004
27. Olsson SE, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9
28. Gerber S. Screening management and costs in the CHUV of Lausanne over a 5 year period. 2007. [Personal communication]
29. Gerber S, Heinzl S. Management of HPV related diseases in Switzerland. 2007. [Personal communication]
30. http://www.tarmed.ch/f.las [last accessed 28 November 2007]
31. http://www.kompendium.ch/ [last accessed 28 November 2007]
32. Arveux P, Bénard S, Bouée S, et al. Invasive cervical cancer treatment costs in France. Bull Cancer 2007;94:219-24
33. Petry KU, Breugelmans JG, Bénard S, et al. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol [in press]
34. Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70
35. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41
36. Bergeron C, Largeron N, McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent Human Papillomavirus vaccine in France. Int J Technol Assess Health Care 2008;24:10-9
37. Ess SM, Schaad UB, Gervaix A, et al. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 2003;21:3273-81
38. Ruedin HJ, Ess S, Zimmermann HP, et al. Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies. Vaccine 2003;21:4145-52
39. Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25:5399-408
40. De Vries R, Van Bergen JAEM, de Jong-van den Berg LTW, et al. Cost-utility of repeated screening for Chlamydia trachomatis. Value in Health 2007;9:1-11
41. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. 2004. [Reference NO515]
42. Neilson A, Freisleben de Blasio B. Økonomisk evaluering av humant papillomavirus (HPV) vaksinasjon i Norge. Oslo: Nasjonalt kunnskapssenter for helsetjenesten (NOKC); 2007. [Nr12-2007]
43. National Board of Health, Danish Centre for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment. Copenhagen: National Board of Health, Danish Centre for Health Technology Assessment, 2007. Series Name: Danish Centre for Health Technology Assessment 2007; 2007 9(1)
44. Thiry N, Lambert M-L, Cleemput I, et al. Vaccination HPV pour la prévention du cancer du col de l'utérus en Belgique: Health Technology Assessment. Health Technology Assessment (HTA). Bruxelles: Centre federal d'expertise des soins de santé (KCE); 2007. KCE reports 64B (D2007/10.273/42)
45. Bergeron C, Breugelmans JG, Bouée S, et al. Cervical cancer screening and associated treatment costs in France. Gynecol Obstet Fertil 2006;34:1036-42
46. Dasbach E, Insinga R, Elbasha E. Assessment of the health and economic impact of a quadrivalent HPV vaccine in the United Kingdom using a transmission dynamic model [abstract]. European Research Organization on Genital Infection and Neoplasia (EUROGIN), Monaco, October 4-6, 2007
47. Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007;165:762-75
48. Newall AT, Beutels P, Good JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007;7:289-96
49. Guidance of the introduction of HPV vaccines in EU countries. 2008: http://ecdc.europa.eu/ [last accessed 14 February 2008]
50. Jakobsson M, Gissler M, Sainio S, et al. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2007;109:309-13
51. Russell RB, Green NS, Steiner CA, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics 2007;120:e1-e9
52. Brown D. HPV Type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18 [abstract G-1720b]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, September17-20, 2007
53. Canfell K, Barnabas R, Patnick J, et al. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004;91:530-6
54. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13 842 women. Br J Cancer 2005;93:575-81
55. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9
56. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93
57. Mitchell MF, Schottenfeld D, Tortolero-Luna G, et al. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;91:626-31
58. Karnon J, Peters J, Platt J, et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004;8:iii, 1-78